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Green Light for Very Early Angiography After Fibrinolysis*Giuseppe Tarantini, MD, PHDSEE PAGE 166F ibrinolysis remains a cornerstone for the treat-ment of ST-segment elevation myocardialinfarction (STEMI) when primary percuta-
neous coronary intervention (PCI) is not readily avail-
able. Its administration in a pre-hospital setting
increases the proportion of patients undergoing rapid
reperfusion with resultant improved outcomes com-
pared with in-hospital administration (1). The logistic
difﬁculties of implementing primary PCI, coupled
with the evidence of beneﬁt of (pre-hospital) ﬁbrino-
lysis administered very early after the onset of symp-
toms, served as foundation for developing a uniﬁed
approach, the “pharmacoinvasive strategy,” to the
management of STEMI patients. In the last decade,
the combination of ﬁbrinolysis with subsequent
routine coronary angiography and PCI (if required)
has been fully studied and compared in randomized
trials with both ﬁbrinolysis alone and/or primary PCI,
and it has been shown to be superior in terms of re-
infarction and recurrent ischemia when compared
with a “watchful waiting” approach, in which angiog-
raphy is indicated only in patients with spontaneous
or induced severe ischemia or left ventricular dysfunc-
tion (2). Accordingly, the American College of Car-
diology Foundation/American Heart Association
guidelines consider the transfer of STEMI patients
treated by ﬁbrinolysis to PCI-capable hospitals for
angiography and PCI, even when hemodynamically
stable and with clinical evidence of successful reper-
fusion, as a Class IIa (Level of Evidence: B) recom-
mendation (3). Stronger is the endorsement of the
pharmacoinvasive strategy provided by the European*Editorials published in JACC: Cardiovascular Interventions reﬂect the
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Level of Evidence: A) (4). A central issue remains the
optimal delay between ﬁbrinolysis and angiography.
On the basis of the 3 most recent trials (NORDISTEMI
[NORwegian study on District treatment of ST-
Elevation Myocardial Infarction] (5), CARESS-in-AMI
[Combined Abciximab Reteplase Stent Study in Acute
Myocardial Infarction] (6), TRANSFER-AMI [Trial of
Routine Angioplasty and Stenting after Fibrinolysis
to Enhance Reperfusion in Acute Myocardial Infarc-
tion] (7), and WEST [Which Early ST-Elevation
Myocardial Infarction Therapy]) (8), all of which had
a median delay between lysis and angiography of
2 to 3 h, a time window of 3 to 24 h after successful
lysis is recommended in both guidelines.To further address this matter, in this issue of
JACC: Cardiovascular Interventions, Madan et al. (9)
utilize the largest available pooled clinical database
using individual patient-level data of 7 randomized
trials, evaluating an early invasive (median time from
ﬁbrinolysis to angiography <12 h) versus a “watchful
waiting” approach. The median symptom onset to
angiography time was 5.3 h. Of 1,238 patients under-
going angiography, 87% underwent PCI (with glyco-
protein IIb/IIIa inhibitor in 63% of the cases), <15%
received DES, and the majority had a femoral vascular
access site. The 30-day and 1-year death or reinfarc-
tion rates, as well as in-hospital major bleeding, were
not inﬂuenced by the different time from ﬁbrinolysis
to angiography, but recurrent ischemia increased
signiﬁcantly when time to angiography was longer
than 4 h (p ¼ 0.02). In contrast, the time from symp-
tom onset to angiography remained a signiﬁcant
predictor of 1-year death or reinfarction and recurrent
ischemia.
The major effect of time from symptom onset
to angiography on outcome is not surprising,
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176considering that 45% of the study patients had inef-
fective reperfusion (Thrombolysis In Myocardial
Infarction ﬂow grade <3) after ﬁbrinolysis. From a
pathophysiologic point of view, a longer symptom
onset to angiography time corresponds to a longer
“true” ischemic time when the occlusion of the infarct
related artery persists (10). As such, it is related to a
more pronounced myocardial and microvascular
injury, larger infarct size, and worse clinical outcome,
even when optimal mechanical reperfusion is applied
(11–13). Additionally, the adverse effect of prolonged
system delay (time from ﬁrst medical contact to
initiation of reperfusion) in terms of mortality and
hospital readmission for congestive heart failure is
well known (14).
More interesting and novel is the reported neutral
effect or potential beneﬁt of the very early (<2 h)
pharmacoinvasive strategy in terms of angina reduc-
tion. Moving from a trial based to a patient-level meta-
analysis permitted the authors to: 1) extrapolate the
data of patients treated very early; and 2) dilute the bias
of the variable angiography performance according to
patient risk in the nonroutine strategy among trials. In
this regard, the angiography rate ranged from >95%
in TRANSFER-AMI (7) and NORDISTEMI (5) to <35% in
CARESS-in-AMI (6) and WEST (8), because these trials
restricted to those patients who needed rescue PCI.
The interplay among baseline patient risk, time delay
from ﬁbrinolysis to angiography, and outcome might
be complex. Thus, although high-risk patients pre-
senting earliermight beneﬁt themost from a short lytic
to angiography time compared with lower-risk pa-
tients or late-comers, a routine early strategy in a real-
world setting could harm unstable patients, for whom
the risks of long interhospital transfers might be
greater than any potential beneﬁt. Notably, in the
TRANSFER-AMI trial, despite the fact that the early
pharmacoinvasive strategy was associated with a sig-
niﬁcant reduction of the composite cardiac endpoint
and a nonsigniﬁcant reduction of death and reinfarc-
tion within 30 days, there was a signiﬁcant inverse
interaction between baseline risk according to GRACE
(Global Registry of Acute Coronary Events) score and
treatment effect (e.g., 16% of higher-risk patients had
harm, whereas lower-risk patients had a beneﬁt).
Notwithstanding, a patient with a lower GRACE score
but with a residual signiﬁcant stenosis of the infarct-
related artery supplying a large territory of viable
myocardium might be the one who beneﬁts most
from a successful very early PCI. On the contrary, in the
older patient with renal dysfunction, diabetes, and
patent infarct-related artery with residual moderate
lesion, even a successful PCI cannot change the
intrinsic high-risk proﬁle according to GRACE score.Accordingly, by multivariate analysis, Madan et al. (9)
found that the prediction model of early and late
adverse outcome was almost entirely grounded in
clinical variables included in the Thrombolysis In
Myocardial Infarction risk score, and that these are
generally irreversible risk factors despite successful
PCI. Nevertheless, in these high-risk patients, adjunc-
tive PCI to lytic might still provide a beneﬁt in terms of
recurrent ischemic events, not necessarily related to
the infarct related artery.
A further argument of discussion is whether a very
early invasive strategy (<2 h), as proposed by the au-
thors, should be differentiated from facilitated PCI.
Besides the lower platelet inhibition in the facilitated
PCI studies, a major difference seems to be that trials
evaluating facilitated PCI compared it with primary
PCI. Exceptions are the STREAM (15) and the GRACIA-2
(Grup de Anãlisis de la Cardiopatia Isquémica Aguda-1)
(16) trials, which indeed had a longer time delay to
adjunctive PCI. With the inherent limitations of
correlating different trials, if we compare the very
early cohort (<2 h) of Madan et al. (9) with the facili-
tated arms of the ASSENT-4 (Assessment of the Safety
and Efﬁcacy of a New Treatment Strategy With Percu-
taneous Coronary Intervention) (17) and FINESSE
(Facilitated Intervention With Enhanced Reperfusion
Speed to Stop Events) (18) trials, the former had a lower
risk proﬁle (30-daymortality rate: 2.6% comparedwith
6% and 5.2%, and 1-year mortality rate: 4% compared
with 7.8% and 6.3%, respectively). Nevertheless, the
early cohort ofMadan et al. (5) still carried an increased
rate of stroke andmajor bleeding that was consistently
higher than that observed in the primary PCI arms of
the aforementioned trials (5.5% vs. 4.4% and 3.6%). In
other words, when available, primary PCI always per-
forms better than facilitated PCI.
In conclusion, we are indebted to the authors for
providing us with more evidence that a pharma-
coinvasive approach without time delay to perform
angiography and PCI (if appropriate) might be the way
to go. Nevertheless, considering that primary PCI, if
available, is better than facilitated PCI, the extramile is
to identify speciﬁc barriers to the implementation of
guidelines and to deﬁne actions to ensure that the
majority of STEMI patients have access to the life-
saving optimal reperfusion therapy (i.e., primary
PCI). This is the mission of the ambitious European
initiative of “Stent for Life” (19).
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